This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Citigroup's Exchange Offer (C)
Greenwood, Robin; Quinn, JamesCase HBS-210015-EFinanceCitigroup faced considerable distress in early 2009. In late 2008, the bank had accepted $45 billion in preferred equity from the United States government via the Troubled Assets Relief Program (TARP). Yet, the stock had continued to slide in early 2009. In late February, the company announced that it would convert as much as $50 billion of preferred stock into common stock, at $3.25 per share. The case asks students to evaluate the pricing of pr...Starting at €5.74
-
NEC Electronics, Teaching Note
Greenwood, Robin; Foley, C. FritzTeaching Note HBS-209028-EFinanceTeaching Note for [209001].Starting at €0.00
-
NEC Electronics
Foley, C. Fritz; Greenwood, Robin; Quinn, JamesCase HBS-209001-EFinanceWhy do shares in NEC Electronics, a publicly listed subsidiary of Japan conglomerate NEC trade at a discount to their fundamental value? Can Perry Capital, a U.S. hedge fund, restructure this subsidiary and generate significant returns? This case provides students with an opportunity to analyze Perry's decision to invest in NEC Electronics. In doing so, it asks for the reasons that NEC might take actions that destroy value and shift value away fr...Starting at €8.20
-
The Proxy Fight at ADP
Greenwood, Robin; Mayfield, E. ScottCase HBS-219052-EFinanceIn July 2017, shares of Automatic Data Processing, Inc. (ADP) surged 12% following a report that the activist investor Bill Ackman had acquired a sizable stake in the company and planned to nominate his own slate of directors at the company's annual meeting in November. Over the months that followed, Ackman and ADP engaged in an increasingly acrimonious battle of words about the future of ADP. Ackman argued that the company was materially underpe...Starting at €8.20
-
Citigroup's Exchange Offer (B)
Greenwood, Robin; Quinn, JamesCase HBS-210004-EFinanceCitigroup faced considerable distress in early 2009. In late 2008, the bank had accepted $45 billion in preferred equity from the United States government via the Troubled Assets Relief Program (TARP). Yet, the stock had continued to slide in early 2009. In late February, the company announced that it would convert as much as $50 billion of preferred stock into common stock, at $3.25 per share. The case asks students to evaluate the pricing of pr...Starting at €5.74
-
Citigroup's Exchange Offer
Greenwood, Robin; Quinn, JamesCase HBS-210009-EFinanceCitigroup faced considerable distress in early 2009. In late 2008, the bank had accepted $45 billion in preferred equity from the United States government via the Troubled Assets Relief Program (TARP). Yet, the stock had continued to slide in early 2009. In late February, the company announced that it would convert as much as $50 billion of preferred stock into common stock, at $3.25 per share. The case asks students to evaluate the pricing of pr...Starting at €8.20
-
MyTime
Begenau, Juliane; Greenwood, RobinCase HBS-217026-EFinanceEthan Anderson, the CEO of San Francisco-based e-commerce company MyTime, must decide on the company's growth strategy. MyTime's first product was a website and mobile app that offered consumers a convenient way to book appointments with local merchants throughout the United States. Student must assess the company's growth strategy and develop a model to value a prospective customer to the company's website.Starting at €8.20
-
Alvogen: Scaling Entrepreneurship, Teaching Note
Kerr, William R.; Isenberg, Daniel J.Teaching Note HBS-820020-EEntrepreneurshipTeaching note for case 819038.Starting at €0.00
-
Leadership at WildChina (B)
Isenberg, Daniel J.; Spence, Shirley M.Case HBS-807128-EEntrepreneurshipSupplements the (A) case.Starting at €5.74
-
Robert Wessman and Actavis' "Winning Formula"
Isenberg, Daniel J.Case HBS-808127-EEntrepreneurshipTo maximize their effectiveness, color cases should be printed in color. Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with 11,000 people, active in 40 countries, global manufacturing, and $1.6 billion. The case explores the reasons for the success of this global venture.Starting at €8.20